Morgan Stanley Maintains Buy Rating and Price Target for Crinetics Pharmaceuticals

Summary

Morgan Stanley has maintained a Buy rating on Crinetics Pharmaceuticals with a $77.00 price target, indicating a 69.90% upside from current levels.Tip Ranks

Impact Analysis

So basically, Morgan Stanley is doubling down on Crinetics Pharmaceuticals, maintaining a Buy rating and setting a $77 price target, which suggests a significant 69.90% upside from current levels.Tip Ranks This is really about their confidence in Crinetics’ growth trajectory, especially following the recent FDA approval of their acromegaly treatment, Palsonify, which is set to launch in October. The market’s missing that this isn’t just a routine reaffirmation; it’s a strong signal that Morgan Stanley sees substantial value creation ahead. Competitors will need to step up their game, and this could attract more institutional interest, driving the stock higher. The risk here is execution—can Crinetics deliver on the high expectations? But if they do, the upside is compelling. I’d read this as a strong buy signal, especially given the broader analyst consensus also leaning towards a Strong Buy with a similar price target.Tip Ranks